Changes in inflammatory status in patients with cancer, as a result of changes in the tumor microenvironment and APP components, have been shown to predict the duration of remission and disease survival in a variety of solid tumors and lymphoid malignancies [11, 15]. The gene discussed is APP; the disease is cancer.